Literature DB >> 30767060

Non-invasive evaluation of the relationship between electrical and structural cardiac abnormalities in patients with myotonic dystrophy type 1.

Lukas Chmielewski1, Michael Bietenbeck1, Alexandru Patrascu2, Sabine Rösch2, Udo Sechtem2, Ali Yilmaz1, Anca-Rezeda Florian3.   

Abstract

BACKGROUND: Cardiac involvement in myotonic dystrophy type 1 (MD1) includes conduction disease, arrhythmias, and left-ventricular (LV) systolic dysfunction leading to an increased sudden cardiac death risk. An understanding of the interplay between electrical and structural myocardial changes could improve the prediction of adverse cardiac events. We aimed to explore the relationship between signs of cardiomyopathy by conventional and advanced cardiovascular magnetic resonance (CMR), and electrical abnormalities in MD1.
METHODS: Fifty-seven MD1 patients (43 ± 13 years, 46% male) and 15 matched controls (41 ± 7 years, 53% male) underwent CMR including cine-imaging with feature-tracking strain analysis, late gadolinium enhancement (LGE), and native/post-contrast T1-mapping with extracellular volume calculation. Standard 12-lead and long-term ECG monitoring were performed as screening for rhythm and/or conduction abnormalities.
RESULTS: Abnormal ECGs were recorded in 40% of MD1; a pathologic CMR was found in 44%: 21% had an impaired LV-EF and 32% showed non-ischemic LGE. When looking at MD1 patients with available long-term ECG monitoring (n = 39), those with atrial fibrillation (Afib)/flutter(Afl) episodes had lower LV-EF (52 ± 7 vs. 60 ± 5%, p = 0.002), lower global longitudinal strain (- 17 ± 3 vs. - 20 ± 3%, p = 0.034), a trend to lower left atrial emptying fraction (LA-EF) (44 ± 14 vs. 55 ± 8%, p = 0.08), and higher prevalence of LGE (88% vs. 23%, p = 0.001) with an intramural (75% vs. 23%, p = 0.01) and septal (63% vs. 13%, p = 0.009) pattern. In a model including LV-EF (OR 0.8, 95% CI 0.7-1.0, p = NS) and LGE presence (OR 14.8, 95% CI 1.4-159.0, p = 0.026), only LGE was independently associated with the occurrence of Afib/Afl episodes.
CONCLUSION: Myocardial abnormalities depicted by non-ischemic LGE-CMR were the only independent predictor for the occurrence of Afib/Afl on ECG monitoring, previously shown to predict adverse cardiac events in MD1.

Entities:  

Keywords:  Atrial fibrillation; Atrial flutter; Cardiovascular magnetic resonance; Inherited cardiomyopathy; Myotonic dystrophy

Mesh:

Year:  2019        PMID: 30767060     DOI: 10.1007/s00392-019-01414-0

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  36 in total

Review 1.  Myotonic dystrophy and the heart.

Authors:  G Pelargonio; A Dello Russo; T Sanna; G De Martino; F Bellocci
Journal:  Heart       Date:  2002-12       Impact factor: 5.994

Review 2.  Expert opinion paper on atrial fibrillation detection after ischemic stroke.

Authors:  Karl Georg Haeusler; Klaus Gröschel; Martin Köhrmann; Stefan D Anker; Johannes Brachmann; Michael Böhm; Hans-Christoph Diener; Wolfram Doehner; Matthias Endres; Christian Gerloff; Hagen B Huttner; Manfred Kaps; Paulus Kirchhof; Darius Günther Nabavi; Christian H Nolte; Waltraud Pfeilschifter; Burkert Pieske; Sven Poli; Wolf Rüdiger Schäbitz; Götz Thomalla; Roland Veltkamp; Thorsten Steiner; Ulrich Laufs; Joachim Röther; Rolf Wachter; Renate Schnabel
Journal:  Clin Res Cardiol       Date:  2018-04-27       Impact factor: 5.460

Review 3.  Left atrial function: physiology, assessment, and clinical implications.

Authors:  Gustavo G Blume; Christopher J Mcleod; Marion E Barnes; James B Seward; Patricia A Pellikka; Paul M Bastiansen; Teresa S M Tsang
Journal:  Eur J Echocardiogr       Date:  2011-05-12

Review 4.  Advances in cardiovascular magnetic resonance in ischaemic heart disease and non-ischaemic cardiomyopathies.

Authors:  Manish Motwani; Ananth Kidambi; John P Greenwood; Sven Plein
Journal:  Heart       Date:  2014-04-02       Impact factor: 5.994

5.  Severity of cardiac conduction involvement and arrhythmias in myotonic dystrophy type 1 correlates with age and CTG repeat length.

Authors:  William J Groh; Miriam R Lowe; Douglas P Zipes
Journal:  J Cardiovasc Electrophysiol       Date:  2002-05

6.  Cardiac involvement in myotonic dystrophy: a nationwide cohort study.

Authors:  Marie Lund; Lars Jorge Diaz; Mattis Flyvholm Ranthe; Helle Petri; Morten Duno; Inger Juncker; Hans Eiberg; John Vissing; Henning Bundgaard; Jan Wohlfahrt; Mads Melbye
Journal:  Eur Heart J       Date:  2014-04-16       Impact factor: 29.983

Review 7.  Pathology of the cardiac conduction system in myotonic dystrophy: a study of 12 cases.

Authors:  H H Nguyen; J T Wolfe; D R Holmes; W D Edwards
Journal:  J Am Coll Cardiol       Date:  1988-03       Impact factor: 24.094

8.  Cardiac involvement and CTG expansion in myotonic dystrophy.

Authors:  Karen Merlevede; Dimitri Vermander; Paul Theys; Eric Legius; Hugo Ector; Wim Robberecht
Journal:  J Neurol       Date:  2002-06       Impact factor: 4.849

9.  Left ventricular systolic function and the pattern of late-gadolinium-enhancement independently and additively predict adverse cardiac events in muscular dystrophy patients.

Authors:  Anca Florian; Anna Ludwig; Markus Engelen; Johannes Waltenberger; Sabine Rösch; Udo Sechtem; Ali Yilmaz
Journal:  J Cardiovasc Magn Reson       Date:  2014-09-25       Impact factor: 5.364

10.  Cardiac Magnetic Resonance-Measured Left Atrial Volume and Function and Incident Atrial Fibrillation: Results From MESA (Multi-Ethnic Study of Atherosclerosis).

Authors:  Mohammadali Habibi; Sanaz Samiei; Bharath Ambale Venkatesh; Anders Opdahl; Thomas M Helle-Valle; Mytra Zareian; Andre L C Almeida; Eui-Young Choi; Colin Wu; Alvaro Alonso; Susan R Heckbert; David A Bluemke; João A C Lima
Journal:  Circ Cardiovasc Imaging       Date:  2016-08       Impact factor: 7.792

View more
  8 in total

Review 1.  Neuromuscular diseases and their cardiac manifestations under the spectrum of cardiovascular imaging.

Authors:  Georgios M Alexandridis; Efstathios D Pagourelias; Nikolaos Fragakis; Maria Kyriazi; Efthymia Vargiami; Dimitrios Zafeiriou; Vassilios P Vassilikos
Journal:  Heart Fail Rev       Date:  2022-07-20       Impact factor: 4.654

2.  Asymptomatic myocardial infarction in a patient with myotonic dystrophy type 1.

Authors:  Yuka Seki; Takanobu Yamada; Arihiro Kiyosue; Koichi Kimura; Masae Uehara; Masaru Hatano; Takayoshi Sasako; Yuichiro Shirota; Atsushi Sudo; Hiroyuki Ishiura; Tatsushi Toda; Toshimasa Yamauchi; Issei Komuro
Journal:  J Cardiol Cases       Date:  2022-06-06

3.  Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.

Authors:  Ramesh S Yadava; Qing Yu; Mahua Mandal; Frank Rigo; C Frank Bennett; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2020-06-03       Impact factor: 6.150

Review 4.  The Added Value of Cardiac Magnetic Resonance in Muscular Dystrophies.

Authors:  Mariana M Lamacie; Jodi Warman-Chardon; Andrew M Crean; Anca Florian; Karim Wahbi
Journal:  J Neuromuscul Dis       Date:  2019

Review 5.  Metabolic Alterations in Myotonic Dystrophy Type 1 and Their Correlation with Lipin.

Authors:  Tiago Mateus; Filipa Martins; Alexandra Nunes; Maria Teresa Herdeiro; Sandra Rebelo
Journal:  Int J Environ Res Public Health       Date:  2021-02-12       Impact factor: 3.390

Review 6.  Cardiac Pathology in Myotonic Dystrophy Type 1.

Authors:  Mani S Mahadevan; Ramesh S Yadava; Mahua Mandal
Journal:  Int J Mol Sci       Date:  2021-11-02       Impact factor: 5.923

7.  Cardiac Involvement and Arrhythmias Associated with Myotonic Dystrophy.

Authors:  Daniel McBride; Amrish Deshmukh; Supriya Shore; Melissa A Elafros; Jackson J Liang
Journal:  Rev Cardiovasc Med       Date:  2022-04-02       Impact factor: 4.430

8.  Rare Disease: Cardiac Risk Assessment With MRI in Patients With Myotonic Dystrophy Type 1.

Authors:  Marco Alì; Caterina Beatrice Monti; Luca Melazzini; Rosanna Cardani; Barbara Fossati; Michele Cavalli; Kelvin Chow; Francesco Secchi; Giovanni Meola; Francesco Sardanelli
Journal:  Front Neurol       Date:  2020-03-19       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.